Gnlb,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

[altolivello]

Il titolo,,,,a livello fondamentali e' messo male,,,,,,,,

ma ha secondo me una buona prospettiva speculativa,,,,,

dietro,,,,,,,,ha holding di rispetto,,,,gli short,,,,assenti,,,

molte possibilita' di approvazione da parte dell'fda,,,di un suo prodotto,,,

biotech,,,,insider in accumulazione da 1,50 dollari,,,

adesso costa poco piu di 2,50 dollari,,,,

insomma potrebbe,,,,,,riemergere,,,,,,credo,,,,

da monitorare,,,,,,,,

allegate vostre impressioni,,,,sempre gradite,,,,,

 

[Trasparente]

x come la vedo io è buona sui 2,3 oppure se passa i 2,8;
naturalmente in una ottica da scalpatina, visto che non ne so di più; ciao.

 

[altolivello]

PARE CHE SIANO DI UNA CERTA IMPORTANZA I COMPARI CHE SONO ANCORA DENTRO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,




Holder Shares % Out Value* Reported
Citigroup Inc. 3,404,200 3.94 $5,242,467 30-Sep-03
Heartland Advisors Inc. 1,536,000 1.78 $2,365,439 30-Sep-03
JP Morgan Chase & Company 1,310,123 1.52 $2,017,589 30-Sep-03
Dimensional Fund Advisors Inc 1,045,300 1.21 $1,609,761 30-Sep-03
Fuller & Thaler Asset Management Inc. 674,241 0.78 $1,038,331 30-Sep-03
Carret and Company, LLC. 443,400 0.51 $682,835 30-Sep-03
Barclays Bank Plc 350,435 0.41 $539,669 30-Sep-03
Ohio-State Teachers Retirement System 151,800 0.18 $233,771 30-Sep-03
Northern Trust Corporation 137,127 0.16 $211,175 30-Sep-03
Furman Selz Capital Management, LLC. 100,000 0.12 $153,999 30-Sep-03


TOP MUTUAL FUND HOLDERS

Holder Shares % Out Value* Reported
Smith Barney Fundamental Value Fund Inc 5,000,000 5.79 $7,699,999 30-Sep-03
Heartland Value Plus Fund 1,200,000 1.39 $1,800,000 30-Jun-03
DFA U.S. Micro Cap Portfolio 366,800 0.42 $652,903 31-May-03
DFA U.S. Small Cap Series 49,600 0.06 $88,287 31-May-03
Russell (Frank) Select Growth Fund 14,000 0.02 $20,720 30-Apr-03
Spartan Extended Market Index Fund 12,200 0.01 $17,323 31-Aug-03
Spartan Total Market Index Fund 9,800 0.01 $13,915 31-Aug-03
SA Fds Inv Tr-U.S. Small Company Fd 5,000 0.01 $7,500 30-Jun-03
Quantitative Master Series Tr-Extended Market Index Seri 2,000 0 $3,000 30-Jun-03
Schwab Cap Tr-Total Stock Market Index Fund 800 0 $1,184 30-Apr-03


View Transactions for Insiders & Institutional Holders

*

 

[g@sfin]

ma questa proprio niente ???? un rimbalzino fino a 1.30 ???? quando si decide ?

 

[elettroscok]

tra non molto

 

[g@sfin]

potrebbe partire per 1$ che ne pensate ????

 

[g@sfin]

compro io e rimane inchiodata ! azzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz

 

[Zantrax]

X Gasfin Ocio

 

[g@sfin]

X Gasfin Ocio

dai almeno un tentativo lo fa ! mi metto in vendita a 0.980

cmq grazie

 

[g@sfin]

X Gasfin Ocio

ricapitolando si sale con volumi della madonna si scende con volumi al lumicino di candela, inoltre a mio parere da perfetto incompetente noto che in area 0.860 ci sono acq. e accumulo (ripeto mio parere) io la provo se va bene se non va LA FACCIO ANDAREEEEEEEEEEEEEEEEEEEEE IOOOOOOOOOOOOOOOOOOOOOOO

con simpatia gas

 

[g@sfin]

sembra tenere......... strano però............. mah...................

 

[g@sfin]

oggi parte !

 

[g@sfin]

oggi parte !

martedì parte !

 

[g@sfin]

martedì parte !

 

[g@sfin]

sicuramente poi lo sapete meglio di me !

 

[g@sfin]

non copratele fallirà ! oggi crolla di un 20% !

 

[Gualt]

non copratele fallirà ! oggi crolla di un 20% !

NEWS?????

 

[pomo d'oro]

delisting? e cosa succederebbe?

dunque, sono dentro e sotto parecchio (in carico a 0,97 circa)...
e non ha tenuto il supporto a 0,7... mi sa che va a 0,5...
ho letto la seguente notizia, e vi chiedo: ma se non riesce entro 6 mesi a tornare sopra al $, e la delistano, cosa succede a chi ne ha le azioni? può ancora trattarla? e dove?

mi preoccupa l'ultimo paragrafo, che non riesco a capire bene...
grazie a chi potrà confortarmi...

sergio


22-Mar-2005
Notice of Delisting or Transfer

Item 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.
On March 21, 2005, Genelabs Technologies, Inc. (the "Company") received a letter from the Nasdaq Stock Market (the "Notice") notifying the Company that for the 30 consecutive trading days preceding the date of the Notice, the bid price of the Company's common stock had closed below the $1.00 per share minimum required for continued inclusion on the Nasdaq National Market pursuant to Nasdaq Marketplace Rule 4450(a)(5). The Notice also stated that the Company has been provided 180 calendar days, or until September 19, 2005, to regain compliance. To do so, the bid price of the Company's common stock must close at or above $1.00 per share for a minimum of ten consecutive trading days prior to that date.

The Company intends to monitor the bid price for its common stock between now and September 19, 2005, and consider various options available to the Company if its common stock does not trade at a level that is likely to regain compliance.

To maintain its listing on the Nasdaq National Market, the Company is also required, among other things, to either maintain stockholders' equity of at least $10 million or a market value of at least $50 million. While we currently satisfy these requirements, we may not continue to satisfy these requirements in the future.

 

[elias]

oggi -22% minini assoluti a 52 week....


Genelabs Announces Preliminary Results of Genovate's Clinical Trial GBL03-00 in Women With Systemic Lupus Erythematosus
4/6/2005 11:00:29 PM






REDWOOD CITY, Calif., April 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- Genelabs Technologies, Inc. (GNLB) announced today results of a preliminary analysis of a Phase III clinical trial conducted by its licensee, Genovate Biotechnology Co., Ltd., which did not demonstrate a statistically significant benefit among the patients receiving prasterone compared to the patients taking placebo. The clinical trial, which was not conducted under a U.S. Investigational New Drug Application (IND), was a randomized, placebo- controlled, double-blind study conducted at six medical centers in Taiwan to determine the effect of prasterone on the bone mineral density of women with systemic lupus erythematosus (SLE or lupus) receiving glucocorticoids. The primary endpoint was bone mineral density at the lumbar spine and the treatment duration was nine months.







MARKETWATCH TOP NEWS
U.S. stocks start mixed
Crude oil back atop $56 a barrel
Wal-Mart shares dip amid lowered forecast
U.S. initial jobless claims fall 19,000 to 334,000




Sign up for FREE e-Newsletters



"Development of a new drug for lupus, a complex and debilitating disease, has proven to be very challenging," stated James A.D. Smith, President and Chief Executive Officer. "When the analysis of this study is complete we plan to meet with the FDA and determine our course of action for Prestara(TM), our formulation of prasterone."

"While we are disappointed by these preliminary results, over the last few years we have also devoted significant resources to discovery of new drugs for treatment of hepatitis C infection, and I am very enthusiastic about our HCV pipeline," continued Mr. Smith. "One of our HCV programs is being conducted in collaboration with Gilead Sciences, under which Genelabs is leading the research efforts, applying nucleoside compounds to the inhibition of HCV. Independent of the Gilead collaboration, another of our HCV discovery programs, to which we retain all rights, has advanced into preclinical development."


up

 

[g@sfin]

amen